ASCO 2017 - High-risk breast cancer: pembrolizumab+standard therapy improved pathologic complete response rates

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • At a maximum tolerated dose of pembrolizumab 200 mg every 3 wk for 4 cycles added to standard therapy in patients with HR+, HER2, and triple-negative breast cancer, the Bayesian probability of superior pathologic control rates was 99.0%.

Why this matters

  • Pembrolizumab is...